Trisalus Life Sciences, Inc.

This study tested a drug called SD-101, given directly into the liver, along with standard immunotherapy, for people with two types of liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma). The goal was to see if the combination was safe and could shrink tum…

This early-stage trial tested a drug called SD-101, given directly into the liver's blood supply, alone or with immune-boosting medicines, for people with a rare eye cancer (uveal melanoma) that spread to the liver. The study aimed to find a safe dose and check if the treatment c…